Ministerio de Industria, Turismo y Comercio LogoMinisterior
 

Alerta

Resultados 152 resultados
LastUpdate Última actualización 11/09/2026 [08:05:00]
pdfxls
Solicitudes publicadas en los últimos 60 días / Last 60 days publications
previousPage Resultados 150 a 152 de 152  

B CELL IMMUNOTHERAPY

NºPublicación:  EP4775668A2 15/07/2026
Solicitante: 
MASSACHUSETTS GEN HOSPITAL [US]
HOLY CROSS HOSPITAL INC [US]
The General Hospital Corporation
Holy Cross Hospital, Inc.
EP_4775668_A2

Resumen de: EP4775668A2

The invention, in general, features a method of treating a neurodegenerative disease (such as amyotrophic lateral sclerosis) or a traumatic brain injury in a subject (e.g., a human) in need thereof, the method comprising administering to the subject a therapeutically effective amount of isolated B cells (such as autologous or allogeneic or xenogeneic B cells).

VANILLIC ACID DERIVATIVE COMPOUND, THERAPEUTIC AGENT COMPOSITION FOR ALZHEIMER'S DISEASE COMPRISING SAME, AND THERAPEUTIC AGENT COMPOSITION FOR NEUROINFLAMMATION

Nº publicación: EP4775203A1 15/07/2026

Solicitante:

THERANOCURE CO LTD [KR]
Theranocure Co., Ltd.

EP_4775203_A1

Resumen de: EP4775203A1

The present invention relates to a vanillic acid derivative compound, which may be formed by a dehydration condensation reaction between vanillic acid and a catecholamine. The vanillic acid derivative compound according to the present invention is characterized in that it can be used as a therapeutic agent for Alzheimer's disease and neuroinflammation.Also, the present invention relates to a pharmaceutical composition for treating Alzheimer's disease and a pharmaceutical composition for treating neuroinflammation, each comprising the above compound.

traducir